|  |
| --- |
|  |
| Paediatric Multisystem Inflammatory Syndrome |
|  |
|  |
|  |
| **Posted : 4th March 2021****Modified: 28th January 2022**  |

**This document has been developed by:**

Dr Ellen Crushell, Consultant Paediatrician & National Clinical Lead for Children

Dr Louise Kyne, Consultant Paediatrician, Dean of the Faculty of Paediatrics

Dr Patrick Gavin Consultant Paediatrician Infectious Diseases

Dr Cathy Gibbons Consultant Paediatric Intensivist

**Please Note: The purpose of this document is to provide guidance for Consultants and other healthcare professionals caring for children presenting with Paediatric Multisystem Inflammatory Syndrome/Multisystem Inflammatory Syndrome in Children.**

## Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2

**Severe COVID-19 continues to be very rare in children.**

**Paediatric Multisystem Inflammatory Syndrome** (**PIMS**) also referred to as Multisystem Inflammatory Syndrome in Children (MIS-C) occurs in less than 0.5% of children following symptomatic or asymptomatic COVID-19 infection. It generally occurs in children who were previously healthy. Children of all ethnicities may be affected but children of black or Asian (non-Chinese) ethnicity are more frequently and more severely affected.

PIMS/MIS-C can be associated with significant morbidity but early appropriate treatment is usually curative. The majority of cases require PICU admission and multidisciplinary input. A high index of suspicion for the condition and early recognition are essential.

Earlier experience from here and elsewhere saw PIMS/MIS-C cases in the weeks following increases in COVID-19 activity in the community.

Following the recent surge of infections in children, please consider this diagnosis in any child or adolescent who appears to have a significant systemic inflammatory response.

**Clinical features include, but are not limited to:** persistent fever, rash, conjunctivitis, and in more severe cases, hypotension/tachycardia and/or shock. **Symptoms and signs may overlap with those of complete or incomplete Kawasaki disease or toxic shock syndromes. Vomiting, diarrhoea and abdominal pain may also be prominent. The majority of cases test negative for SARS-CoV-2 by PCR.**

**When PIMS/MIS-C is suspected, please contact Paediatric Infectious Diseases Team, CHI at Temple Street to guide further investigation and management. If the child has signs of shock or might benefit from Intensive Care please contact the PICU referral line on 1800-222378.**

### Useful Resources

RCPCH. PIMS: guidance document for Clinicians: <https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-%20inflammatory%20syndrome-20200501.pdf>

A consensus document for the management of PIMS-TS has been developed (Feb2021) [https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(20)30304-7/fulltext](https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642%2820%2930304-7/fulltext)

PIMS: the COVID-19 linked syndrome affecting children - information for families <https://www.rcpch.ac.uk/resources/pims-covid-19-linked-syndrome-affecting-children-information-families>